Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17045048 | 0.88 | LTA4H (0.41) | LTA4HHSD17B10PARP10CA12CA1 | |
| SCHEMBL19471202 | 0.78 | LTA4H (0.47) | LTA4HPARP10LMNAMAPTMEN1 | |
| SCHEMBL14893048 | 0.77 | CA12 (0.45) | HSD17B10PARP10LMNAMAPTMEN1 | |
| SCHEMBL17274979 | 0.72 | LTA4H (0.47) | LTA4HRECQL | |
| SCHEMBL17275059 | 0.72 | MAPK10 (0.46) | LTA4HPARP10LMNAMAPTMEN1 | |
| SCHEMBL1583078 | 0.72 | THRA (0.47) | TSHR | |
| SCHEMBL17275010 | 0.72 | LMNA (0.47) | LTA4HPARP10LMNAMAPTMEN1 | |
| SCHEMBL7866685 | 0.71 | LTA4H (0.51) | LTA4HMAPTMEN1KMT2A | |
| SCHEMBL17275067 | 0.71 | LMNA (0.43) | LTA4HHSD17B10PARP10LMNAMAPT | |
| SCHEMBL9861929 | 0.70 | ESR1 (0.46) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9393235-B2 | Pyridone amides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150246028-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2015-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246028-A1 | PYRIDONE AMIDES AS MODULATORS OF SODIUM CHANNELS | SCN5A, SCN1A, KCNJ2 | LTA4H 1453/4885HSD17B10 1766/4885PARP10 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.